
The Society for Immunotherapy of Cancer (SITC) published it's first clinical practice guideline (CPG) on immunotherapy for the treatment of Acute Leukemia in the
Journal for ImmunoTherapy of Cancer on October 19, 2020.
SITC's Cancer Immunotherapy Guidelines program is a collection of CPGs developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics. This Acute Leukemia CPG was developed collaboratively through the efforts of an expert panel that convened to discuss the current therapeutic landscape and covers FDA-approved immunotherapies for acute lymphoblastic and acute myeloid leukemia, as well as discussion of promising emerging treatment modalities, and patient quality of life issues.